Skip to content

2. Public-Private Mix (PPM) for TB care and prevention

This dashboard presents data from seven countries defined as top global priorities for public-private mix (PPM) initiatives.

2.1 PPM contribution

PPM contribution to TB diagnosis by health facility ownership at primary care, 2023

2.1.1 PPM contribution to TB diagnosis in public sector, 2023

2.1.2 PPM contribution to TB diagnosis in the private for profit sector, 2023

2.1.3 PPM contribution to TB diagnosis in private not for profit sector, 2023

PPM contribution to TB diagnosis by health facility ownership at secondary/tertiary care, 2023

2.1.4 PPM contribution to TB diagnosis at public sector, 2023

2.1.5 PPM contribution to TB diagnosis at private for profit sector, 2023

2.1.6 PPM contribution to TB diagnosis at private not for profit sector, 2023

2.1.7 Contribution of public-private mix and public-public mix initiatives to case notifications of people diagnosed with TB (absolute number)

2.1.8 Contribution of public-private mix and public-public mix initiatives to case notifications of people diagnosed with TB (%)

2.2 Rapid testing for TB

Percentage of people diagnosed with new episode of TB who were initially tested with WRD

2.2.1 Overall percentage by facility ownership

2.2.2.Percentage by facility ownership at primary care

2.2.3 Percentage by facility ownership at secondary/tertiary care

2.3 Bacteriological confirmation

Percentage of people whose disease was bacteriologically confirmed among people with new episode of pulmonary TB

2.3.1 Overall percentage by facility ownership

2.3.2 Percentage by facility ownership at primary care

2.3.3 Percentage by facility ownership at secondary/tertiary care

2.4 Testing for drug-resistant TB

Percentage of people diagnosed with bacteriologically confirmed pulmonary TB who were tested for rifampicin susceptibility

2.4.1 Overall percentage by facility ownership

2.4.2 Percentage by facility ownership at primary care

2.4.3 Percentage by facility ownership at secondary/tertiary care

2.5 Treatment initiation

Percentage of people diagnosed with TB and started on TB treatment

2.5 Treatment outcome

Percentage of TB patients who were successfully treated out of those who started TB treatment

2.5.1 Overall percentage by facility ownership, 2022

2.5.2 Percentage by facility ownership at primary care, 2022

2.5.3 Percentage by facility ownership at secondary/tertiary care, 2022

2.6 TB preventive treatment

Number of household contacts (or all close contacts) who were started TB preventive treatment

2.6.1 Overall number by facility ownership

2.6.2 Number by facility ownership at primary care

2.6.3 Number by facility ownership at secondary/tertiary care

Percentage of household contacts (or all close contacts) who were started TB preventive treatment

2.6.4 Overall percentage by facility ownership

2.6.5 Percentage by facility ownership at primary care

2.6.6 Percentage by facility ownership at secondary/tertiary care

Metadata

Glossary and definitions

Public-private mix              

Public-private mix (PPM) refers to engagement by the NTP with private sector providers of TB care. Examples include private individual and institutional providers, the corporate or business sector, mission hospitals, nongovernmental organizations and faith-based organizations.

 Public-public mix

Public-public mix refers to engagement by the NTP with public health sector providers of TB care that are not under the direct purview of the NTP. Examples include public hospitals, public medical colleges, prisons and detention centres, military facilities and public health insurance organizations.

Public health facilities

Health facilities owned and operated by government entities (federal, state, or local).

Private for-profit health facilities

Facilities owned by individuals or companies and aim to generate profit.

Private non-profit health facilities

Facilities owned by organizations that are not intended to distribute profits to owners or shareholders, but bay still generate revenue to support operations.

Primary care

Primary care is a subset of Primary health care (PHC) and refers to essential, first-contact care provided in a community setting. 

Secondary/tertiary care

Secondary care is specialist care provided on an ambulatory or inpatient basis, usually following a referral from primary care. Tertiary care includes highly specialized services in ambulatory and hospital settings or in a facility that has personnel and facilities for advanced medical investigation and treatment. 

Number of people diagnosed with new episode of TB 

The number of new and recurrent cases of TB detected in a given year, including those with an unknown previous TB treatment history. All forms of TB are included, including cases in people living with HIV and those with drug-resistant TB. Case detection refers to the diagnosis of TB in a person, which is then reported within the national surveillance system (also known as notification) and subsequently to WHO.

Molecular WHO-recommended rapid diagnostic test 

Diagnostic tests approved by WHO that employs molecular-based techniques for the diagnosis of tuberculosis (TB).

Bacteriologically confirmed TB

A person from whom a bacteriological specimen is positive by a WHO recommended rapid diagnostic test, culture, or smear microscopy.

Testing for drug susceptibility

In vitro testing of a strain of M. Tuberculosis complex using either:               1) molecular, genotypic techniques to detect resistance-conferring mutations; or 2) phenotypic methods to determine susceptibility to a medicine. 

TB treatment initiation

The initiation of an appropriate treatment regimen for a person with TB disease.  Note: It is recommended to monitor this step in the pathway of care because diagnosis of TB disease does not necessarily mean that a person will be offered or accept to take treatment. 

Preventive TB treatmentTreatment offered to individuals who are considered at risk of progression from TB infection to TB disease. Also referred to as treatment of TB infection, treatment for latent TB infection or TB preventive therapy.

Copyright and licensing

Copyright

Attribution 4.0 International (CC BY 4.0)

License

The World Health Organization (“WHO”) encourages public access and use of the data that it collects and publishes on its web site data.who.int. The data are organized in datasets and made available in machine-readable format (“Datasets”). The Datasets have been compiled from data provided by WHO’s Member States under the WHO policy on the use and sharing of data collected by WHO in Member States outside the context of public health emergencies.

Use of the data derived from the Datasets, which may appear in formats such as tables and charts, is also subject to these Terms and Conditions. Datasets may include data describing the Dataset called “Metadata”. If any datasets are credited to a source other than WHO, then those materials are not covered by these Terms and Conditions, and permission should be sought from the source provided. You are responsible for determining if this is the case, and if so, you are responsible for obtaining any necessary permission from the sources indicated. The risk of claims resulting from infringement of any third-party-owned component in the materials rests solely with you.

You may use our application programming interfaces (“APIs”) to facilitate access to the Datasets, whether through a separate web site or through another type of software application. By using the Datasets or any presentations of data derived from them, or by using our APIs in connection with the Datasets, you agree to be bound by these Terms and Conditions, as may be amended from time to time by WHO at its sole discretion.

Unless specifically indicated otherwise, these Datasets are provided to you under a Creative Commons Attribution 4.0 International License (CC BY 4.0), with the additional terms below. The basic terms applicable to the CC BY 4.0 license may be accessed here. By downloading or using the Datasets, you agree to comply with the terms of the CC BY 4.0 license, as well as the following mandatory and binding addition:

Any dispute relating to the interpretation or application of this license shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the parties or, in the absence of agreement, with the UNCITRAL Arbitration Rules. The parties shall accept the arbitral award as final.

Permission typePublicly accessible
Prohibited uses

You shall not attempt to de-anonymise the Datasets or use the Datasets in a manner that falsifies or misrepresents their content.

You shall not, in connection with your use of the Datasets published on data.who.int, state or imply that WHO endorses, or is affiliated with, you, or that WHO endorses your use of data.who.int, or any content, output, or analysis resulting from or related to the data.who.int, or any entity, organization, company, product or services.

Citation

World Health Organization 2025 data.who.int, WHO TB dashboard [Dashboard]. https://data.who.int/dashboards/tuberculosis/

Disclaimer

WHO reserves the right at any time and from time to time to modify or discontinue, temporarily or permanently, the Datasets, or any means of accessing or utilizing the Datasets with or without prior notice to you.

Maps
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the accuracy of the Datasets. However, the Datasets are being provided without warranty of any kind, either expressed or implied. You will be solely responsible for your use of the Datasets. In no event shall WHO be liable for any damages arising from such use.

For full disclaimers, terms of use and your indemnification of WHO, please visit Terms and Conditions.